Antiglutamate Anticonvulsants in the Treatment of Alcohol Withdrawal Syndrome

This study has been completed.
Sponsor:
Information provided by:
St. Petersburg State Pavlov Medical University
ClinicalTrials.gov Identifier:
NCT00241995
First received: October 17, 2005
Last updated: October 17, 2006
Last verified: October 2005
  Purpose

The study is aimed to evaluate the efficacy of antiglutamate anticonvulsants (topiramate, lamotrigine, and memantine) in the treatment of alcohol withdrawal syndrome


Condition Intervention
Topiramate
Lamotrigine
Memnatine
Diazepam
Placebo
Drug: Anticonvulsants

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment

Further study details as provided by St. Petersburg State Pavlov Medical University:

  Eligibility

Ages Eligible for Study:   20 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Alcohol dependence Alcohol withdrawal syndrome

Exclusion Criteria:

Drug dependence Major psychiatric diagnoses Severe somatic illness

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00241995

Sponsors and Collaborators
St. Petersburg State Pavlov Medical University
Investigators
Principal Investigator: Evgeny M Krupitsky, MD, PhD St. Petersburg State Pavlov Medical University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00241995     History of Changes
Other Study ID Numbers: RCT-RCT_LOND_GAT_AWS_2003
Study First Received: October 17, 2005
Last Updated: October 17, 2006
Health Authority: Russia: Ministry of Health of the Russian Federation

Additional relevant MeSH terms:
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 26, 2014